Efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes: A double‐blind randomized controlled trial (INICOM study)

BACKGROUND: Gemigliptin is a new dipeptidyl peptidase‐IV inhibitor. We investigated the efficacy and safety of initial combination therapy with gemigliptin and metformin compared with monotherapy with either drug in patients with type 2 diabetes (T2D). METHODS: A total of 433 T2D patients with a gly...

Descripción completa

Detalles Bibliográficos
Autores principales: Lim, Soo, Han, Kyung Ah, Yu, JaeMyung, Chamnan, Parinya, Kim, Eun Sook, Yoon, Kun‐Ho, Kwon, Sam, Moon, Min Kyong, Lee, Kwan Woo, Kim, Dong‐Jun, Kim, Mikyung, Wongtanate, Manaj, Kim, Eun Young, Kim, Sung‐Ho, Lee, Moon‐Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811802/
https://www.ncbi.nlm.nih.gov/pubmed/27619558
http://dx.doi.org/10.1111/dom.12787

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5811802/
https://www.ncbi.nlm.nih.gov/pubmed/27619558
http://dx.doi.org/10.1111/dom.12787

Ejemplares similares